

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



石四藥集團有限公司

SSY Group Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2005)

VOLUNTARY ANNOUNCEMENT UPDATE ON PRODUCT DEVELOPMENT

The board of directors (the “Board”) of SSY Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce the updates on product development of the Group as follows:

1. The Group, being the second of the PRC entities, has obtained the approval for drug production and registration for Emedastine Difumarate Eye Drops 0.05% (0.35ml : 0.175mg in terms of $C_{17}H_{26}N_4O$) from National Medical Products Administration of China (the “NMPA”), being under type 4 chemical drug and regarded as passing the consistency evaluation. This product is mainly used for temporary relief of the signs and symptoms of allergic conjunctivitis.
2. The Group, being the third of the PRC entities, has obtained the approval for drug production and registration for Perindopril Arginine Tablets (5mg) from the NMPA, being under type 4 and regarded as passing the consistency evaluation. This product is mainly used for the treatment of hypertension and congestive heart failure.
3. The Group has obtained the approvals for drug production and registration for Peramivir and Sodium Chloride Injection 100ml (Peramivir 0.3g and 0.15g in terms of $C_{15}H_{28}N_4O_4$ and Sodium Chloride 0.9g) from the NMPA, being under type 4 and regarded as passing the consistency evaluation. This product is mainly used for the treatment of influenza A and B.
4. The Group has obtained the approval for Bumetanide Injection (1ml: 0.5g) from the NMPA, being under type 3 and regarded as passing the consistency evaluation. This product is mainly used for the treatment of hypertension and edematous diseases, and is also used for prevention of acute renal failure and for the treatment of hyperkalemia, hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion (SIADH), acute drug or toxin poisoning and cases where furosemide is ineffective. As stated in the Company’s announcement dated 16 March 2026, the Group’s Bumetanide bulk drug has obtained the approval for registration from the NMPA to become a bulk drug for the preparations on the market.

This announcement is a voluntary announcement made by the Company to keep the shareholders and potential investors informed of the latest business development of the Group.

By order of the Board
Chow Hing Yeung
Executive Director and Company Secretary

Hong Kong, 21 May 2026

As at the date of this announcement, the Board comprises Mr. Qu Jiguang, Mr. Su Xuejun, Mr. Meng Guo, Mr. Chow Hing Yeung and Ms. Qu Wanrong as executive Directors, Mr. Liu Wenjun as non-executive Director, and Mr. Wang Yibing, Mr. Chow Kwok Wai and Mr. Jiang Guangce as independent non-executive Directors.